Literature DB >> 33762792

Late Onset Macular Oedema in a Patient with Multiple Sclerosis Treated with Fingolimod.

Anna Camós-Carreras1, Salut Alba-Arbalat2, Marina Dotti-Boada1, Alba Parrado-Carrillo1, Carolina Bernal-Morales1, Albert Saiz2, Bernardo Sánchez-Dalmau1.   

Abstract

Macular oedema is a rare complication of fingolimod treatment. It usually presents within 3-4 months, but occasionally presents later. It can resolve without treatment despite continuation of fingolimod treatment. Herein we report a case of very late onset macular oedema in a 49-year-old woman with multiple sclerosis treated with fingolimod for 7 years. The patient presented with blurred vision in both eyes with visual acuities of 20/32 in her right eye and 20/25 in her left eye. She had macular oedema, that without discontinuing fingolimod treatment, resolved after 1 month.
© 2020 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Macular oedema; fingolimod; multiple sclerosis; retina

Year:  2020        PMID: 33762792      PMCID: PMC7946040          DOI: 10.1080/01658107.2020.1821065

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  8 in total

1.  Cystoid macular edema associated with fingolimod use for multiple sclerosis.

Authors:  Armin R Afshar; Joshua K Fernandes; Ravi D Patel; Susan M Ksiazek; Veeral S Sheth; Anthony T Reder; Seenu M Hariprasad
Journal:  JAMA Ophthalmol       Date:  2013-01       Impact factor: 7.389

2.  Management of fingolimod-associated macular edema.

Authors:  Jeanie Chui; Geoffrey K Herkes; Andrew Chang
Journal:  JAMA Ophthalmol       Date:  2013-05       Impact factor: 7.389

Review 3.  Fingolimod-associated macular edema: incidence, detection, and management.

Authors:  Nieraj Jain; M Tariq Bhatti
Journal:  Neurology       Date:  2012-02-28       Impact factor: 9.910

4.  Real-world incidence of fingolimod-associated macular oedema.

Authors:  Li Yen Goh; Varo Kirthi; Eli Silber; Joshua P Harvey; Timothy L Jackson
Journal:  Mult Scler Relat Disord       Date:  2020-04-28       Impact factor: 4.339

5.  Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.

Authors:  Marco A Zarbin; Lee M Jampol; Rama D Jager; Anthony T Reder; Gordon Francis; William Collins; Dejun Tang; Xiaoli Zhang
Journal:  Ophthalmology       Date:  2013-03-24       Impact factor: 12.079

Review 6.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

7.  LETTER TO THE EDITOR Screening for Fingolimod Associated Macular Oedema: Experience Versus Guidelines.

Authors:  R Moosavi; F Bremner; J Acheson
Journal:  Open Ophthalmol J       Date:  2014-10-03

Review 8.  New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ® tablets.

Authors:  Gianfranco Vitiello; Lucia Maltagliati; Oliviero Rossi
Journal:  Clin Mol Allergy       Date:  2020-06-11
  8 in total
  3 in total

1.  Fingolimod-associated severe bilateral cystoid macular edema.

Authors:  Hideki Fukuoka; Kentaro Kojima; Ayako Iwama; Takahiro Okumura; Chie Sotozono
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-22

2.  Diagnosis and Management of Fingolimod-Associated Macular Edema.

Authors:  Chunjiang Wang; Zhenzhen Deng; Liying Song; Wei Sun; Shaoli Zhao
Journal:  Front Neurol       Date:  2022-07-15       Impact factor: 4.086

3.  Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.

Authors:  Bruce Ac Cree; Krzysztof W Selmaj; Lawrence Steinman; Giancarlo Comi; Amit Bar-Or; Douglas L Arnold; Hans-Peter Hartung; Xavier Montalbán; Eva K Havrdová; James K Sheffield; Neil Minton; Chun-Yen Cheng; Diego Silva; Ludwig Kappos; Jeffrey A Cohen
Journal:  Mult Scler       Date:  2022-06-28       Impact factor: 5.855

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.